Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation (MINI) Act.
Literal federal measure citations: H.R. 1672
2025 · 1st Quarter (Jan 1 - Mar 31)
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS)
Filed by TIBER CREEK GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 18, 2025
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- TIBER CREEK GROUP
- Filing UUID
- 87e49785-9d59-4e22-bb1c-56ca49727144
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340B Drug Pricing Program; General intellectual property issues; Issues related to drug pricing; Issues related to pharmacy benefit managers.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.